NCT00255281已完成2 期
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 160
- 试验地点
- 32
- 主要终点
- The proportion of patients that have converted from AF within 90 minutes from start of infusion.
研究概览
简要总结
The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity
排除标准
- •Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium <3.8 mmol/L or >5.0 mmol/L. QTc(Bazett) >450 ms. Any QRS duration >150 ms
结局指标
主要结局
The proportion of patients that have converted from AF within 90 minutes from start of infusion.
次要结局
- The time to conversion of AF from start of the infusion.
研究者
研究点 (32)
Loading locations...
相似试验
已完成
1 期
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsFGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast CancerNCT01202591AstraZeneca127
已完成
1 期
Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.HealthyNCT00799747AstraZeneca56
已完成
1 期
Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017HealthyNCT00791752AstraZeneca40
已完成
1 期
Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral DosesDiabetes Mellitus Type 2NCT00841048AstraZeneca107
已完成
2 期
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic PatientsAsthma PatientsNCT01197794AstraZeneca1,144